Compare DRIO & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRIO | CPIX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 73.6M |
| IPO Year | 2013 | 2007 |
| Metric | DRIO | CPIX |
|---|---|---|
| Price | $8.42 | $3.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 7.7K | ★ 134.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.70 |
| EPS | ★ 9.05 | N/A |
| Revenue | $7,394,000.00 | ★ $42,010,949.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.15 | N/A |
| P/E Ratio | $0.99 | ★ N/A |
| Revenue Growth | ★ 43.02 | 16.75 |
| 52 Week Low | $0.38 | $1.85 |
| 52 Week High | $17.74 | $6.27 |
| Indicator | DRIO | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.60 | 34.95 |
| Support Level | $0.56 | $2.78 |
| Resistance Level | $12.36 | $3.85 |
| Average True Range (ATR) | 0.62 | 0.32 |
| MACD | -0.16 | -0.12 |
| Stochastic Oscillator | 18.74 | 7.93 |
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.